Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
Prelude Therapeutics (NASDAQ: PRLD) announced promising initial clinical data for PRT3789, its first-in-class SMARCA2 degrader, in a Phase 1 trial. The drug showed encouraging anti-tumor activity in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer. Key findings include:
- 3 confirmed partial responses observed
- 7 out of 26 evaluable NSCLC or esophageal patients showed tumor shrinkage
- Generally well-tolerated safety profile with no dose-limiting toxicities
- Dose escalation continuing to 9th cohort (500mg once weekly)
The company plans to confirm the biologically active dose for PRT3789 monotherapy by year-end and advance combination studies with docetaxel. These results represent initial proof of concept for selective SMARCA2 degradation in certain SMARCA4 mutated cancers.
Prelude Therapeutics (NASDAQ: PRLD) ha annunciato dati clinici iniziali promettenti per PRT3789, il suo degrader di SMARCA2 di prima classe, in uno studio di Fase 1. Il farmaco ha mostrato un'attività antitumorale incoraggiante in pazienti con cancro polmonare non a piccole cellule (NSCLC) mutato per SMARCA4 e cancro esofageo. I risultati chiave includono:
- 3 risposte parziali confermate osservate
- 7 su 26 pazienti valutabili affetti da NSCLC o cancro esofageo hanno mostrato riduzione del tumore
- Profilo di sicurezza generalmente ben tollerato senza tossicità correlate alla dose
- L'escursione della dose continua fino alla 9a coorte (500 mg una volta alla settimana)
La società prevede di confermare la dose biologicamente attiva per la monoterapia con PRT3789 entro la fine dell'anno e di avanzare negli studi di combinazione con il docetaxel. Questi risultati rappresentano una prova iniziale di concetto per la degradazione selettiva di SMARCA2 in alcuni tumori mutati per SMARCA4.
Prelude Therapeutics (NASDAQ: PRLD) anunció datos clínicos iniciales prometedores para PRT3789, su degradador de SMARCA2 de primera clase, en un ensayo de Fase 1. El medicamento mostró una actividad antitumoral alentadora en pacientes con cáncer de pulmón no microcítico (NSCLC) mutado por SMARCA4 y cáncer esofágico. Los hallazgos clave incluyen:
- 3 respuestas parciales confirmadas observadas
- 7 de 26 pacientes evaluables con NSCLC o cáncer esofágico mostraron reducción del tumor
- Perfil de seguridad generalmente bien tolerado sin toxicidades limitantes de dosis
- La escalada de dosis continúa hasta la novena cohorte (500 mg una vez por semana)
La empresa planea confirmar la dosis biológicamente activa para la monoterapia con PRT3789 a finales de año y avanzar en estudios de combinación con docetaxel. Estos resultados representan la prueba inicial de concepto para la degradación selectiva de SMARCA2 en ciertos cánceres mutados por SMARCA4.
프렐류드 테라퓨틱스(NASDAQ: PRLD)는 1상 시험에서 첫 번째 클래스인 SMARCA2 분해제 PRT3789의 유망한 초기 임상 데이터를 발표했습니다. 이 약물은 SMARCA4 변이가 있는 비소세포 폐암(NSCLC) 및 식도암 환자에서 고무적인 항종양 활성을 나타냈습니다. 주요 발견 사항은 다음과 같습니다:
- 3건의 확인된 부분 반응 관찰
- 26명의 평가 가능한 NSCLC 또는 식도암 환자 중 7명이 종양 축소를 보였습니다
- 일반적으로 잘 견디는 안전성 프로필로 용량 제한 독성이 없음
- 9번째 집단(500mg 주 1회)으로 증량을 계속 진행 중
회사는 연말까지 PRT3789 단일 요법의 생물학적으로 활성인 용량을 확인하고 독시탁셀과의 병용 연구를 진행할 계획입니다. 이러한 결과는 특정 SMARCA4 변이 암에서 선택적 SMARCA2 분해에 대한 초기 개념 증명을 나타냅니다.
Prelude Therapeutics (NASDAQ: PRLD) a annoncé des données cliniques initiales prometteuses pour PRT3789, son dégradeur de SMARCA2 de première classe, lors d'un essai de Phase 1. Le médicament a montré une activité anti-tumorale encourageante chez des patients atteints de cancer du poumon non à petites cellules (NSCLC) et de cancer de l'œsophage mutés pour SMARCA4. Les principales conclusions comprennent :
- 3 réponses partielles confirmées observées
- 7 sur 26 patients évaluables atteints de NSCLC ou de cancer de l'œsophage ont montré une réduction de la tumeur
- Profil de sécurité généralement bien toléré sans toxicités limitant la dose
- L'escalade de dose se poursuit jusqu'à la 9e cohorte (500 mg une fois par semaine)
L'entreprise prévoit de confirmer la dose biologiquement active pour la monothérapie avec PRT3789 d'ici la fin de l'année et de faire avancer les études de combinaison avec le docétaxel. Ces résultats représentent une preuve de concept initiale pour la dégradation sélective de SMARCA2 dans certains cancers mutés pour SMARCA4.
Prelude Therapeutics (NASDAQ: PRLD) hat vielversprechende erste klinische Daten für PRT3789, seinen erstklassigen SMARCA2-Degenerator, in einer Phase-1-Studie bekannt gegeben. Das Medikament zeigte ermutigende anti-tumorale Aktivität bei Patienten mit SMARCA4-mutiertem nichtkleinzelligem Lungenkrebs (NSCLC) und Speiseröhrenkrebs. Zu den wichtigsten Ergebnissen gehören:
- 3 bestätigte partielle Ansprechen beobachtet
- 7 von 26 evaluierbaren NSCLC- oder Speiseröhrenkrebspatienten zeigten eine Tumorrückbildung
- Im Allgemeinen gut verträgliches Sicherheitsprofil ohne dosislimitierende Toxizitäten
- Dosissteigerung geht bis zur 9. Kohorte (500 mg einmal wöchentlich) weiter
Das Unternehmen plant, die biologisch aktive Dosis für die Monotherapie mit PRT3789 bis zum Jahresende zu bestätigen und Kombinationsstudien mit Docetaxel voranzutreiben. Diese Ergebnisse stellen einen ersten Machbarkeitsbeweis für die selektive SMARCA2-Abbau bei bestimmten SMARCA4-mutierten Krebserkrankungen dar.
- 3 confirmed partial responses observed in NSCLC and esophageal cancer patients
- 7 out of 26 evaluable NSCLC or esophageal patients showed tumor shrinkage
- Generally well-tolerated safety profile with no dose-limiting toxicities
- Dose escalation continuing to 9th cohort (500mg once weekly)
- One patient remains on study for over 1 year, demonstrating prolonged stable disease
- No tumor shrinkage observed in 20 patients with tumor types other than NSCLC and esophageal cancer at current dose levels
The interim Phase 1 data for PRT3789, Prelude's SMARCA2 degrader, shows promising early signs of efficacy and safety in SMARCA4-mutated cancers. Key highlights:
- Objective responses observed in 3 out of 26 evaluable NSCLC/esophageal cancer patients
- 7 patients showed tumor shrinkage
- Generally well-tolerated safety profile with no dose-limiting toxicities
- Pharmacodynamic data demonstrates selective SMARCA2 degradation
While encouraging, this is still early-stage data with a small patient sample. The continued dose escalation and enriched cohorts will be critical to determine optimal dosing and confirm efficacy signals. The selection for a plenary session at EORTC-NCI-AACR suggests high interest from the oncology community in this novel approach.
This data represents a significant milestone for Prelude Therapeutics, providing initial proof-of-concept for their lead asset PRT3789. Key implications for investors:
- Validates Prelude's platform and approach to SMARCA2 degradation
- Positions the company as a leader in this novel target space
- Potential for accelerated development path if efficacy is confirmed
However, it's important to note that further data is needed to fully assess the drug's potential. The
The Phase 1 trial design and execution appear robust, with several noteworthy aspects:
- Inclusion of pharmacodynamic markers to confirm mechanism of action
- Adaptive design allowing for backfill cohorts in responsive tumor types
- Parallel exploration of combination therapy with docetaxel
The absence of dose-limiting toxicities through 8 cohorts is encouraging, potentially allowing for higher, more efficacious doses. The observed exposure-response relationship supports continued dose escalation. However, the heterogeneity in SMARCA4 mutations (Class 1 vs Class 2) may complicate patient selection and efficacy analysis. Future trials should focus on refining biomarker strategies to identify the most responsive patient populations.
- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789 monotherapy dose escalation
- At doses studied to date, PRT3789 was generally well-tolerated with no dose-limiting toxicities or study drug-related serious adverse events
- Company to host investor conference call and webcast on Friday, September 13, 2024 at 12:00 PM EST
WILMINGTON, Del., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the first interim clinical data from its ongoing Phase 1 open-label, dose-escalation trial of PRT3789, a first-in-class SMARCA2 degrader, highly selective for SMARCA2 and designed to treat cancer patients with a SMARCA4 mutation. The data were presented at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain.
The study investigators reported that, as of the August 5, 2024 data cutoff date (the Cutoff Date), 65 patients were safety evaluable, enrolled and treated. This included 46 efficacy evaluable patients (with a post-baseline scan) with any tumor type harboring any SMARCA4 mutation.
As reported today by the study investigators, PRT3789 was generally well-tolerated through 8 dosing cohorts. Dose escalation continues, now in the 9th dosing cohort. The majority of adverse events reported by investigators have been mild to moderate. A maximum tolerated dose has not yet been identified.
Overall, of the 26 advanced, heavily pre-treated NSCLC or esophageal patients evaluable for efficacy, 7 had tumor shrinkage. RECIST confirmed partial responses (PRs) were observed in 3 patients. Additional patients demonstrated clinical benefit as measured by prolonged stable disease (SD) including one patient on treatment for more than 1 year.
“For cancer patients harboring a SMARCA4 mutation, the disease is particularly aggressive and prognosis with current standard of care is quite poor,” stated Robin Guo, M.D., Memorial Sloan Kettering Cancer Center. “The observation of durable stable disease and tumor regressions in Phase I monotherapy dose escalation, coupled with a tolerable emerging safety profile, is encouraging. This is what we hope to see with a first-in-class new therapy for a novel target in patients with a high unmet need.”
“We are encouraged by the early clinical activity and emerging safety profile observed to date with PRT3789,” stated Jane Huang, M.D., President and Chief Medical Officer of Prelude. “These data represent initial proof of concept that selective SMARCA2 degradation can yield antitumor activity in certain SMARCA4 mutated cancers.”
Continued Dr. Huang, “Monotherapy dose escalation continues, now at cohort 9 (500mg once weekly) with backfill cohorts continuing to enroll enriched for NSCLC and esophageal cancer patients with Class 1 mutations. We intend to confirm the biologically active dose for PRT3789 as monotherapy by year-end and continue to advance monotherapy and docetaxel combination studies in parallel to best position PRT3789 as a new treatment option for patients suffering from this aggressive type of cancer.”
PRT3789 Interim Phase 1 Results
PRT3789 is currently being evaluated in an ongoing dose-escalation Phase 1 trial in patients with solid tumors harboring any SMARCA4 mutation refractory to standard of care and generally multiple lines of therapy in most patients. As of the Cutoff Date, 65 patients with advanced cancer have been treated at eight dose levels (24 mg QW, 48 mg QW, 80 mg QW, 120 mg QW, 160 mg QW, 212 mg QW, 283 mg QW, 376 mg QW). The median age of these patients is 62 and the median number of prior treatments was 3 (ranging from 1-10). 34 patients (
Initial Safety Data
PRT3789 was generally well-tolerated in the 65 patients treated as of the Cutoff Date. Adverse events are reported regardless of attribution to study drug. Adverse events of any grade observed to date consisted of nausea (
Pharmacokinetic (PK) and Pharmacodynamic (PD) Data
Preliminary PK data was available from 24 mg to 376 mg dose cohorts. A general trend of increases in exposure (Cmax, AUC) with dose was observed. Mean concentrations were observed above SMARCA2 plasma DC50 (21 nM) for approximately 8 hours at the 376 mg dose. No accumulation was observed with repeat dose administration, consistent with the half-life and once-weekly administration. PD effect observed was more prolonged than PK half-life, reaching trough inhibition of 70
Analysis of Initial Clinical Activity
As of the Cutoff Date, there were 46 efficacy evaluable patients with a post-baseline scan across all tumor types with any SMARCA4 mutation. Of the 26 advanced, heavily pre-treated NSCLC or esophageal patients who were evaluable for efficacy, 7 had tumor shrinkage. RECIST confirmed partial responses (PRs) were observed in 3 patients (2 esophageal, 1 NSCLC). Tumor shrinkage was observed in patients with both Class 1 and Class 2 SMARCA4 mutations. Additional patients on study demonstrated clinical benefit as measured by prolonged SD. One patient remains on study having been treated for more than 1 year. Of the 20 patients with tumor types other than NSCLC and esophageal cancer, none demonstrated tumor shrinkage at dose levels studied to date.
Conference Call and Webcast Information
Prelude Therapeutics management team will host a conference call, live webcast with slides and a Q&A on Friday, September 13, 2024 at 12:00 PM ET. A live webcast of the presentation will be available at Events & Presentations - Prelude Therapeutics (preludetx.com). A replay of the webcast will be available shortly after the conclusion of the call at Events & Presentations - Prelude Therapeutics (preludetx.com) and archived on the Company’s website for 60 days following the call.
Interim Phase 1 data selected for Plenary Session at upcoming EORTC-NCI-AACR Symposium
Interim Phase 1 data for PRT3789 was also selected for a Plenary Session oral presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The presentation titled, “First Clinical Results from a Phase 1 Trial of PRT3789, a First-in-Class SMARCA2 Degrader, in Patients with Advanced Solid Tumors with a SMARCA4 Mutation,” will be presented by Timothy Yap, M.D. from University of Texas MD Anderson Cancer Center. The presentation is scheduled for October 24, 2024 at 10:00 AM CEST (4:00 AM EST) as part of the Proffered Papers: Advancing Patient Care Through Novel Clinical Trials session.
About PRT3789 – A first-in-class, highly selective, intravenous SMARCA2 degrader
PRT3789 is a first-in-class SMARCA2 degrader, highly selective for SMARCA2 and designed to treat patients with a SMARCA4 mutation. Cancer patients whose tumors have SMARCA4 mutations have a poor prognosis and as a result, this is an area of high unmet medical need.
PRT3789 is in Phase 1 clinical development in biomarker selected SMARCA4 mutant patients. Enrollment remains on track, and the Company expects to conclude monotherapy dose escalation in 2024 and identify a recommended Phase 2 dose. In addition, enrollment of patients into back-fill cohorts enriched for NSCLC and SMARCA4 loss-of-function mutations is ongoing, as is enrollment of the docetaxel combination cohort.
Objectives for this first Phase 1 clinical trial are to establish the safety and tolerability profile of PRT3789 as both monotherapy and in combination with docetaxel, evaluate activity, pharmacokinetics and pharmacodynamics and determine a dose and potential indications for advancement into registrational clinical trial(s).
Prelude launched an educational video series focused on the science of SMARCA biology, the discovery of first-in-class, highly selective SMARCA2 degraders and the unmet medical need for patients with SMARCA4 mutated cancer. This series can be found on the Company’s website under Highly Selective SMARCA2 Degraders - Prelude Therapeutics (preludetx.com).
About Prelude Therapeutics
Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. For more information, visit preludetx.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and clinical development activities for Prelude’s product candidates, the potential safety, efficacy, benefits and addressable market for Prelude’s product candidates, and the expected timeline for concluding the monotherapy dose escalation and identifying the biologically active dose, and expected ongoing work on and development of PRT3789. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “continue,” “will,” “schedule,” and “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on the Company’s current expectations and projections about future events and various assumptions. Although Prelude believes that the expectations reflected in such forward-looking statements are reasonable, Prelude cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Prelude's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Prelude's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, clinical trial sites and our ability to enroll eligible patients, supply chain and manufacturing facilities, Prelude’s ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, Prelude's ability to fund development activities and achieve development goals, Prelude's ability to protect intellectual property, and other risks and uncertainties described under the heading "Risk Factors" in Prelude’s Annual Report on Form 10-K for the year ended December 31, 2023, its Quarterly Reports on Form 10-Q and other documents that Prelude files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Prelude undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof, except as may be required by law.
Investor Contact:
Robert A. Doody, Jr.
Senior Vice President, Investor Relations
Prelude Therapeutics Incorporated
484.639.7235
rdoody@preludetx.com
FAQ
What were the key results of Prelude Therapeutics' Phase 1 trial for PRT3789 (PRLD)?
What types of cancer did PRT3789 (PRLD) show efficacy against in the Phase 1 trial?
What is the mechanism of action of Prelude Therapeutics' PRT3789 (PRLD)?
What are Prelude Therapeutics' next steps for PRT3789 (PRLD) based on the Phase 1 results?
